Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment.
Kawashima S, Inozume T, Kawazu M, Ueno T, Nagasaki J, Tanji E, Honobe A, Ohnuma T, Kawamura T, Umeda Y, Nakamura Y, Kawasaki T, Kiniwa Y, Yamasaki O, Fukushima S, Ikehara Y, Mano H, Suzuki Y, Nishikawa H, Matsue H, Togashi Y. Kawashima S, et al. Among authors: inozume t. J Immunother Cancer. 2021 Nov;9(11):e003134. doi: 10.1136/jitc-2021-003134. J Immunother Cancer. 2021. PMID: 34795004 Free PMC article.
PD-1 blockade therapy promotes infiltration of tumor-attacking exhausted T cell clonotypes.
Nagasaki J, Inozume T, Sax N, Ariyasu R, Ishikawa M, Yamashita K, Kawazu M, Ueno T, Irie T, Tanji E, Morinaga T, Honobe A, Ohnuma T, Yoshino M, Iwata T, Kawase K, Sasaki K, Hanazawa T, Kochin V, Kawamura T, Matsue H, Hino M, Mano H, Suzuki Y, Nishikawa H, Togashi Y. Nagasaki J, et al. Among authors: inozume t. Cell Rep. 2022 Feb 1;38(5):110331. doi: 10.1016/j.celrep.2022.110331. Cell Rep. 2022. PMID: 35108529 Free article.
Mixed Response to Cancer Immunotherapy is Driven by Intratumor Heterogeneity and Differential Interlesion Immune Infiltration.
Morinaga T, Inozume T, Kawazu M, Ueda Y, Sax N, Yamashita K, Kawashima S, Nagasaki J, Ueno T, Lin J, Ohara Y, Kuwata T, Yukami H, Kawazoe A, Shitara K, Honobe-Tabuchi A, Ohnuma T, Kawamura T, Umeda Y, Kawahara Y, Nakamura Y, Kiniwa Y, Morita A, Ichihara E, Kiura K, Enokida T, Tahara M, Hasegawa Y, Mano H, Suzuki Y, Nishikawa H, Togashi Y. Morinaga T, et al. Among authors: inozume t. Cancer Res Commun. 2022 Jul 28;2(7):739-753. doi: 10.1158/2767-9764.CRC-22-0050. eCollection 2022 Jul. Cancer Res Commun. 2022. PMID: 36923281 Free PMC article.
CD106 in tumor-specific exhausted CD8+ T cells mediates immunosuppression by inhibiting TCR signaling.
Naoi Y, Morinaga T, Nagasaki J, Ariyasu R, Ueda Y, Yamashita K, Zhou W, Kawashima S, Kawase K, Honobe-Tabuchi A, Ohnuma T, Kawamura T, Umeda Y, Kawahara Y, Nakamura Y, Kiniwa Y, Yamasaki O, Fukushima S, Kawazu M, Suzuki Y, Nishikawa H, Hanazawa T, Ando M, Inozume T, Togashi Y. Naoi Y, et al. Among authors: inozume t. Cancer Res. 2024 Apr 18. doi: 10.1158/0008-5472.CAN-23-0453. Online ahead of print. Cancer Res. 2024. PMID: 38635899
Induced pluripotent stem cell-derived myeloid cells expressing OX40 ligand amplify antigen-specific T cells in advanced melanoma.
Kimura T, Fukushima S, Okada E, Kuriyama H, Kanemaru H, Kadohisa-Tsuruta M, Kubo Y, Nakahara S, Tokuzumi A, Kajihara I, Makino K, Miyashita A, Aoi J, Makino T, Tsukamoto H, Nishimura Y, Inozume T, Zhang R, Uemura Y, Senju S, Ihn H. Kimura T, et al. Among authors: inozume t. Pigment Cell Melanoma Res. 2020 Sep;33(5):744-755. doi: 10.1111/pcmr.12887. Epub 2020 May 18. Pigment Cell Melanoma Res. 2020. PMID: 32353897
73 results